The JAK1/JAK2 inhibitor LN3103801 prevents/reverses hyperglycemia by dual blockade of IFN-γ-mediated MHC-I overexpression in beta-cells and γc cytokine-driven T-cell activation, without compromising antitumor efficacy in NOD mice (63). Here, JAK2 is linked to Hyperglycemia.